12:00 AM
 | 
Jul 21, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ZS-9: Completed Phase III enrollment

ZS Pharma completed enrollment of 258 patients with hyperkalemia in the international Phase III ZS004 trial evaluating oral ZS-9. Patients are receiving 10 g ZS-9 thrice daily for 48 hours in the open-label acute phase. Patients who achieve normokalemia then receive 5,...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >